AbstractRisperidone belongs to a class of antipsychotic agents, the benzisoxazole derivatives.1 It is a selective monoaminergic antagonist with unique properties. It has a high affinity for serotoninergic 5-HT2 and dopaminergic D2 receptors.2,3 Risperidone also binds to alpha-1 adrenergic receptors and, with lower affinity, to H1 histamine and alpha-2 adrenergic receptors. Risperidone has no affinity for cholinergic receptors. The antipsychotic activity of risperidone is considered to be due to both risperidone and its active metabolite, 9-hydroxyrisperidone. As a potent D2 antagonist, risperidone improves the positive symptoms of schizophrenia and causes less depression of motor activity and induction of catalepsy than classical neuroleptics. Balanced central serotonin and dopamine antagonism may reduce extrapyramidal side effect liability and extend the therapeutic activity to the negative and affective symptoms of schizophrenia.1 Risperidone is available as a tablet formulation in strengths of 0.5 mg, 1 mg, 2 mg, 3 mg or 4 mg.1,2 An oral solution (1 mg/mL) and a prolonged-release intramuscular injection are also available.1
Focus on ...
By submitting manuscripts to SAPJ, authors of original articles are assigning copyright to Medpharm Publications (Pty) Ltd. Authors may use their own work after publication without written permission, provided they acknowledge the original source. Individuals and academic institutions may freely copy and distribute articles published in SAPJ for educational and research purposes without obtaining permission.